Φορτώνει......
Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib
PURPOSE: When during cancer treatment resistance to a tyrosine kinase inhibitor (TKI) occurs, switching to another TKI is often considered as a reasonable option. Previously, we reported that resistance to sunitinib may be caused by increased lysosomal sequestration, leading to increased intracellul...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Cell Oncol (Dordr) |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Springer Netherlands
2015
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4555235/ https://ncbi.nlm.nih.gov/pubmed/25665527 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13402-015-0218-8 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|